Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. Despite advances in modern therapy, patients with relapsed or metastatic disease have a very poor clinical prognosis. Fibroblast Growth Factor Receptor 4 (FGFR4) is a cell surface tyrosine kinase receptor that is involved in no...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Samuel Q Li, Adam T Cheuk, Jack F Shern, Young K Song, Laura Hurd, Hongling Liao, Jun S Wei, Javed Khan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2013-01-01
coleção:	PLoS ONE
Acesso em linha:	http://europepmc.org/articles/PMC3790700?pdf=render
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!